The U.S. Judicial Panel on Multidistrict Litigation (JPML) created several new multidistrict litigations last month, including two that involved medical products used to treat thousands of people. According to a Transfer Order dated August 14th, all federal IVC filter lawsuits involving C.R. Bard, Inc.’s Recovery and G2 inferior vena cava filters will be consolidated before a single judge in the District of Arizona. A second Order issued on the same day established a centralized proceeding in the District of Minnesota for peripheral neuropathy claims involving Levaquin and other fluoroquinolone antibiotics.

C.R. Bard IVC Filter Litigation

The August 14th Order consolidates 22 IVC filter cases currently pending in federal courts, as well as any that might be filed in the future. All of the cases were brought on behalf of individuals who allegedly suffered complications related to the breakage and/or migration of Bard’s Recovery and G2 retrievable inferior vena cava filters. The devices are intended to be implanted in the inferior vena cava, so as to prevent blood clots from traveling to the lungs.

The Bard Recovery Filter was brought to market in 2003, and replaced by the G2 just two ears later. IVC filter plaintiffs claim that both products suffer from design defects that place patients at risk for embolization, blood vessel punctures, organ perforation, and death.

In choosing Arizona as the venue for the IVC filter litigation, the JPML noted that the state is a primary place of business for C.R. Bard and other defendants.

Levaquin Peripheral Neuropathy Litigation

The new fluoroquinolone litigation will involve dozens of Avelox, Cipro and Levaquin lawsuits filed on behalf of individuals who allegedly developed peripheral neuropathy and permanent nerve damage while using the popular antibiotics.

Fluoroquinolone labels have mentioned peripheral neuropathy as a side effect since 2004. But stronger language was added in 2013 to better reflect the rapid onset of the condition and the potential for permanent nerve damage. Plaintiffs who have since filed Levaquin lawsuits and other claims accuse the drugs’ manufacturers of failing to provide the public with warnings that adequately described the potential for this serious adverse event.

The District of Minnesota is also the venue for Levaquin lawsuits involving the medication’s alleged association with serious tendon injuries. Court records indicate that the majority of claims filed in that proceeding have been resolved.

Free Legal Reviews Now Available

Bernstein Liebhard LLP is now offering free legal reviews to individuals who may have suffered serious IVC filter complications, as well as those who were diagnosed with peripheral neuropath following treatment with Levaquin or another fluoroquinolone antibiotic. To discuss your case with one of our attorneys, please call 877-779-1414.

Published September 9, 2015 by